Mr. Albini has served as our Chief Financial Officer since January 2013. During 2012, Mr. Albini served as a consulting Chief Financial Officer for Carbylan Biosurgery, a company focused on the development and commercialization of advanced biomaterial-based joint therapies. From 2011 to 2016, Mr. Albini also served as Chief Financial Officer and Secretary for Itero Holdings, LLC, a successor entity to Itero Biopharmaceuticals, Inc., a company focused on the development and commercialization of protein therapeutics, at which Mr. Albini served as Chief Financial Officer and Senior Vice President from 2009 to 2011. Previously, Mr. Albini served as Chief Financial Officer of Novacea, Inc. and Lynx Therapeutics, Inc., both biopharmaceutical companies. Mr. Albini worked for more than 14 years in various financial management positions at Genentech, Inc., including director of financial planning and analysis and director of finance for international operations. Mr. Albini received a B.S.C in Accounting from Santa Clara University and an M.B.A. from the Walter A. Haas School of Business at the University of California, Berkeley. Mr. Albini is also a certified public accountant (inactive status) in California.
Chief Financial Officer
Shabbir Anik, Ph.D.
Chief Technical Operations Officer
Dr. Shabbir Anik has over 30 years in the pharmaceutical and biotech industry. His expertise spans drug development, pharmaceutical technologies, manufacturing operations, strategic alliances and the contract services business. Shabbir joins us from Onyx/Amgen where he was Senior Vice President, Technical Operations since 2011. Prior to joining Onyx he was the Chief Executive Officer of Althea, a contract manufacturing organization. Previously, he was President, Global Pharmaceutical Development Services and Chief Scientific Officer for Patheon. Shabbir also held leadership positions at Neurex, Oread and Syntex. He received his Ph.D., Pharmaceutical Sciences at the University of Wisconsin, Madison.
Chief People and Communications Officer
Linda joined Sutro Biopharma in January 2008. She serves as the Chief People and Communication Officer at Sutro Biopharma and is a co-founder of Parallax Venture Partners, an early-stage health care venture fund. Currently, in her role, Linda provides strategic guidance to Sutro Biopharma in the areas of human capital and corporate communications. Prior to her work with Sutro Linda headed the human resources and corporate communications strategy for a variety of publically held biotechnology companies including playing a pivotal role as part of senior management,moderating board compensation committee meetings and serving as an active participant in board of directors’ meetings. Prior to joining Sutro Biopharma, Linda was the Vice President of Human Resources and Corporate Communications at Gilead where she had responsibility for these functions in addition to information technology, facilities and engineering, purchasing and the information center. Linda has also served as Director of Investor Relations and Director of Compensation, Benefits and Systems with Genentech, Inc. In addition, she is the President elect of the Leadership Advisory Board, and a past Board member and immediate past President of the San Mateo Public Library Foundation, serving a six year term, a past Board Member and former Secretary and Treasurer for CuriOdyssey, a environmental and science educational museum, serving a six year term, Current Board member and past President of A Home Within, a national organization focused on foster care and mental health, Past Treasurer and Board Member of National Charity League’s Crystal Springs Chapter, a former member of the Board of Directors and Co-President for the Hillsborough Schools Foundation, past APG President for the Hillsborough School District, past Chair of the Biotechnology Industry Association (BIO) Human Resources committee, a past board member of the Northern California Boys and Girls Club. Linda was honored as Hillsborough’s Citizen of the Year in 2011. Linda graduated with honors from San Francisco State University with a degree in Business, Psychology and Sociology.
Trevor Hallam, Ph.D.
Chief Scientific Officer
Dr. Hallam brings more than 25 years of experience in drug discovery and development to Sutro. Most recently, he was executive vice president of research & development and executive officer at Palatin Technologies where he was responsible for discovery and clinical development and led the development of several INDs for drug candidates in a variety of therapeutic areas. Prior to joining Sutro, Dr. Hallam held several senior management positions at AstraZeneca, most recently vice president, biologics (respiratory and inflammatory diseases), vice president, U.S. medical affairs, and vice president, preclinical research and development, respiratory and inflammation, Sweden. He began his pharmaceutical career at Smith Kline & French Research, U.K., followed by senior management positions at Glaxo Group Research, U.K., Roche Research Centre, U.K., and Rhone Poulenc Rorer, U.S. Dr. Hallam conducted his post-doctoral training in the laboratory of Timothy J. Rink, M.D., Sc.D., at the Physiological Laboratory, University of Cambridge after receiving his Ph.D. in biochemistry from King’s College, University of London.
VP Technology and Innovation
Mr. Heinsohn has over 24 years of process development and manufacturing experience related to recombinant protein production. He came to Sutro after working at Genentech for 17 years, where he held the role of Senior Scientist and Senior Group Leader for process development, early stage purification activities. While at Genentech, he developed large-scale protein recovery processes, supported research and development activities and participated in regulatory filings for VEGF, thrombopoeitin, Lucentis, and other novel protein therapeutics. He was CMC team leader for the development and launch of Avastin. Prior to joining Genentech, Henry was employed by Genencor International where he was Senior Scientist. Previously, he was a scientist at Corning Medical and Scientific. Henry received a B.S. in Chemistry from North Carolina State University, and conducted postgraduate studies in Biochemistry at the Boston University.
Robert Kiss, Ph.D.
VP Process & Analytical Development
Dr. Robert Kiss has over 26 years of process development and manufacturing experience in the biotechnology industry. Bob came to Sutro after working at Genentech for nearly 24 years, where he most recently held the role of Distinguished Engineer and Senior Director of Late Stage Cell Culture process development. While at Genentech, he was directly involved in the development and initial licensure of the cell culture processes for Rituxan®, Herceptin®, Perjeta®, Tecentriq®, and Ocrevus™, the design and startup of the Vacaville manufacturing sites, and the transfer of multiple cell culture processes to Genentech/Roche and partner sites around the world. He is globally-recognized for expertise in bioprocess scale-up, glycosylation of CHO-derived recombinant proteins, and virus barriers to protect mammalian cell culture processes. He received his chemical engineering degrees from UC Davis (B.S.) and the Massachusetts Institute of Technology (M.S., Ph.D.), is a Fellow in the American Institute of Medical and Biological Engineering, and is a licensed engineer in the state of California. Bob was elected to the National Academy of Engineering in 2019.
Mark Lupher, Jr., Ph.D.
VP Translational Pharmacology & Preclinical Development
Dr. Mark Lupher joins Sutro with over twenty years of biomedical research and development experience from discovery through translational clinical development with both biologics and small molecules. He has been an active consultant for Sutro’s preclinical and translational initiatives for over one year. In his earlier position as chief scientific officer of Promedior, Dr. Lupher oversaw several IND applications and early clinical development programs for phase I and phase II clinical trials, as well as Promedior’s drug discovery, preclinical development and intellectual property portfolio. Previously, at ICOS Corporation and Immunex Corporation, he led various drug discovery programs. Dr. Lupher received his Ph.D. in Immunology from Harvard University in Cambridge, MA.
Andreas Maderna, Ph.D.
Vice President, Chemistry
Dr. Maderna joins the Sutro team after spending the majority of his career at Pfizer in the department of oncology medicinal chemistry. As an associate research fellow, he led multiple chemistry design teams in hit to lead optimization campaigns of small molecule programs directed at various immuno-oncology, cell singling and epigenetic targets. Dr. Maderna’s expertise also includes antibody drug conjugates (ADC’s). At Pfizer, he led the payload discovery and development efforts to support Pfizer’s antibody drug conjugate portfolio. His team developed new and highly potent payloads that led to multiple ADC clinical candidates. For his contributions Dr. Maderna received the 2015 Pfizer Worldwide Research and Development Individual Achievement Award. Before joining Pfizer Dr. Maderna was the project leader of multiple oral kinase inhibitor projects at Wyeth and Valeant Pharmaceuticals. He discovered the MEK inhibitor Refametinib which has been investigated in multiple phase 1 and phase 2 studies. Dr. Maderna obtained his Ph.D. in Chemistry at the University of Heidelberg, Germany. He is the author of over thirty publications and presentations and is the co-inventor on over fifteen patents and patent applications.
Arturo Molina, M.D., M.S.
FACP, Chief Medical Officer
Dr. Arturo Molina, an oncologist, has led scientific innovation and driven clinical programs forward for over twenty years. With his extensive experience interacting with the FDA and other global regulatory bodies, he has led the development of hematological and oncologic clinical candidates from phase I through phase III and through post-marking trials. He joins Sutro from his former role as VP of oncology and scientific innovation at Johnson & Johnson’s California Innovation Center where he was involved in the evaluation of novel biologics and small molecules, with a focus on immuno-oncology. While working for Johnson & Johnson, Dr. Molina oversaw the approval of Zytiga® in a multitude of countries for metastatic castration resistant prostate cancer indications. Previously, Dr. Molina served as chief medical officer and executive vice-president of Cougar Biotechnology where his leadership efforts advanced the company’s abiraterone program, Zytiga®, from phase I into several global phase III studies. He played a substantial role in the diligence efforts which led to the near $1B acquisition of Cougar by Johnson & Johnson. Dr. Molina has also held leadership positions at Biogen Idec where he led the hematology/oncology clinical development team and oversaw the post-approval label expansion of Rituxan® in front-line follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Dr. Molina was a faculty staff physician and adjunct professor in hematology/bone marrow transplantation and medical oncology/therapeutics research at the City of Hope Comprehensive Cancer Center. Dr. Molina received his M.D. and M.S. degrees from Stanford University School of Medicine in Stanford, CA. He trained in internal medicine and medical oncology at Stanford University Medical Center and is board-certified in these specialties, He has an active California medical license and is a staff physician (volunteer) in the Oncology Clinic at the Veterans Affairs Palo Alto Health Care System. Dr. Molina is also an Adjunct Clinical Associate Professor (volunteer) in the Department of Medicine, Division of Oncology, Stanford University School of Medicine and is President-Elect of the Stanford Medical Alumni Association. He has co-authored more than 120 publications in peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, Blood, Lancet Oncology, Biology of Blood and Marrow Transplantation and Annals of Oncology.
William J. Newell
Chief Executive Officer
Mr. Newell has over 20 years of senior management experience in the biotechnology industry. He joined Sutro Biopharma as CEO in January 2009. Previously, he served as the President of Aerovance, Inc., a venture-backed company developing clinical assets for respiratory diseases. Mr. Newell also was Chief Business Officer and Senior Vice President at publicly-traded QLT, Inc. and served in several senior management positions at public-traded Axys Pharmaceuticals, Inc. For the 15 years prior to joining Axys, Mr. Newell practiced corporate law in the San Francisco Bay Area. He is presently a member of the Board at SutroVax Inc. Mr. Newell is also a Board member on BIO’s Emerging Companies Section and Health Section and Chairman of the Board and a member of the Executive Committee of the California Life Sciences Association.
Nicki Vasquez, Ph.D.
SVP Alliance Management/Portfolio Strategy & Operations
Dr. Vasquez brings over 20 years of biopharmaceutical discovery research and development experience to Sutro. Most recently, she was Vice President of Program & Portfolio Management at StemCells, Inc. , where she was responsible for establishing program management for research and clinical stage programs exploring HuCNS-SC stem cell therapy for Alzheimer’s Disease, spinal cord injury and dry AMD. Prior to that she was at Elan, where she held positions of increasing responsibility from Alzheimer’s Disease and autoimmune discovery research, to Vice President Research Operations & Program Management, and Vice President Development Program & Portfolio Management. Dr. Vasquez obtained her doctoral degree in immunology from the University of California, San Diego, and received her post-doctoral training at Genentech.
Stephen T. Worsley
Chief Business Officer
Stephen T. Worsley has served as our Chief Business Officer since September 10, 2018. From October 2017 to August 2018, Mr. Worsley served as Sr. Vice President, Business Development for Indi Molecular, Inc., an emerging life sciences company that is developing a synthetic class of diagnostic and therapeutic agents with antibody-like properties: protein-catalyzed capture agents. From November 2013 to October 2017, Mr. Worsley served as Vice President of Business Development for Peregrine Pharmaceutical, Inc., now Avid BioServices, Inc, a biopharmaceutical company developing immuno-oncology related antibodies and manufacturing of biopharmaceutical products. Prior to Peregrine, Mr. Worsley held several senior management positions in various pharmaceutical companies, including Centrose Pharmaceutical, Inc., Intrexon Corporation, Raven Biotechnologies, Inc. and Abgenix, Inc. Mr. Worsley also previously served on the Board of Directors of Peregrine Beijing, Ltd. Mr. Worsley received a B.S. in International Economics and Finance from the University of Utah and an M.B.A. in Finance from the University of Washington.